Inventor · disambiguated record
Ulrike Philippar
Also filed as: PHILIPPAR ULRIKE
6 granted patents·12 pending applications·10 citations·filing 2017–2025
73Inventor score
Top patents by PatentIndex Score
18 records- 0190US10954214B2Pyrazole derivatives as MALT1 inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Mar 23, 2021·5 cites·37 claims
- 0280US10888550B2Pyrazole derivatives as MALT1 inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2019·Granted Jan 12, 2021·3 cites·10 claims
- 0376US11040031B2Pyrazole derivatives as MALT1 inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2019·Granted Jun 22, 2021·2 cites·9 claims
- 0468US2025043019A1TRISPECIFIC ANTIBODY TARGETING CD79b, CD20, AND CD3JANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 0567US2025188163A1Gprc5d antibodies with enhanced effector function and uses thereofJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 0664US12077521B2Pyrazole derivatives as MALT1 inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Sep 3, 2024·0 cites·18 claims
- 0760US12103977B2Trispecific antibody targeting CD79b, CD20, and CD3JANSSEN BIOTECH INC·Filed 2022·Granted Oct 1, 2024·0 cites·35 claims
- 0859US2023012167A1Inhibitors of bruton's tyrosine kinase and methods of their useJANSSEN PHARMACEUTICA NV·Filed 2022·Application pending·0 cites
- 0958US2023013755A1Inhibitors of bruton's tyrosine kinase and methods of their useJANSSEN PHARMACEUTICA NV·Filed 2022·Application pending·0 cites
- 1058US2024409634A1CD33 x Vd2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCERJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 1158US2025376509A1Methods for treatment of myeloproliferative neoplasmsJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 1257US2022267438A1Trispecific antibody targeting bcma, gprc5d, and cd3JANSSEN PHARMACEUTICA NV·Filed 2022·Application pending·0 cites
- 1351US11872220B2Methods and compositions for treating B-cell malignanciesJANSSEN PHARMACEUTICA NV·Filed 2022·Granted Jan 16, 2024·0 cites·32 claims
- 1451US2025361317A1Bispecific antibody targeting emr2 (cd312) and the t-cell receptor trbv19JANSSEN BIOTECH INC·Filed 2025·Application pending·0 cites
- 1551US2022288058A1Combination therapy using a malt1 inhibitor and a btk inhibitorJANSSEN PHARMACEUTICA NV·Filed 2022·Application pending·0 cites
- 1647US2021155990A1Nf-kb regulated gene expression assay for assessing efficacy of malt1 inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2020·Application pending·0 cites
- 1745US2024299376A1Method of treating a condition using a therapeutically effective dose of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamideJANSSEN PHARMACEUTICA NV·Filed 2021·Application pending·0 cites
- 1844US2021156865A1Methods for assessing efficacy of malt1 inhibitors using an nf-kb translocation assayJANSSEN PHARMACEUTICA NV·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ulrike Philippar files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →